Featured Research

from universities, journals, and other organizations

Alternative approach to treating diabetes tested

Date:
June 10, 2011
Source:
Mayo Clinic
Summary:
In a mouse study, scientists have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.

In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.

In type 2 diabetes, the body stops responding efficiently to insulin, a hormone that controls blood sugar. To compensate for the insensitivity to insulin, many diabetes drugs work by boosting insulin levels; for example, by injecting more insulin or by increasing the amount of insulin secreted from the pancreas. The new study, published in the June 9 issue of PLoS ONE, showed that a different approach could also be effective for treating diabetes -- namely, blocking the breakdown of insulin, after it is secreted from the pancreas.

"Insulin levels in the blood reflect the balance between how much is secreted and how fast it is broken down," says the study's lead researcher, Malcolm A. Leissring, Ph.D., from Mayo Clinic's Department of Neuroscience. "Blocking the breakdown of insulin is simply an alternative method for achieving the same goal as many existing diabetes therapies."

The researchers tested this idea by studying mice in which insulin-degrading enzyme (IDE) was "knocked out," or deleted genetically. IDE is a molecular "machine" that normally chews up the insulin hormone, breaking it down into smaller pieces. Levels of insulin in the blood are controlled, in part, by this process.

Compared to normal mice, IDE knockout mice had more insulin overall, weighed less, and were more efficient at controlling their blood sugar. They were, in effect, "super mice" with respect to their ability to lower their blood sugar after a meal, the process that is disrupted in diabetes, explains Dr. Leissring.

These findings suggest that drugs that inhibit IDE could be useful in treating diabetes. Dr. Leissring's team is actively working to develop such drugs. As reported in a separate study in PLoS ONE last year, Dr. Leissring and colleagues developed the first potent and selective inhibitors of IDE. The Mayo team has now developed more drug-like IDE inhibitors that they are preparing to test in animal models of diabetes.

"The reason we studied IDE knockout mice was to help us understand whether IDE inhibitors would be useful for treating diabetes," says Samer Abdul-Hay, Ph.D., first author on the study. But the IDE knockout mice are not a perfect model of how a drug will perform, he notes. "They are actually a better model of overdosing on an IDE inhibitor. We would never want a drug that inhibits IDE 100 percent in all tissues throughout life."

The effect of deleting all IDE in the mice was so strong, in fact, that the effect eventually backfired, the researchers say. Despite being "super mice" when young, as the IDE knockout mice aged, they slowly became resistant to the elevated insulin, gained weight, and lost control of their blood sugar. As a result, the older mice developed classic type 2 diabetes.

"The finding that older IDE knockout mice develop diabetes has confused a lot of people," says Dr. Leissring. "It's an example of too much of a good thing becoming bad for you." Drugs that inhibit IDE only partially or only transiently would not be expected to cause diabetes, he says. "Deleting all IDE is overkill."

The researchers say the Mayo study also has interesting implications for understanding how diabetes starts. "Deleting IDE produces elevated insulin levels -- a condition known as hyperinsulinemia. Diabetes is usually believed to cause hyperinsulinemia, not the other way around," Dr. Leissring says. Nevertheless, in the IDE knockout mice, chronic hyperinsulinemia seemed to actually cause diabetes. As they aged, the mice appeared to adapt to the chronically high insulin levels, for example, by reducing the number of receptors for insulin in their tissues. "These adaptations make the mice less sensitive to insulin, which is the exact cause of type 2 diabetes."

Whether these findings apply to humans is unclear, Dr. Leissring cautions. He says these novel findings "represent early, but exciting days" in a new avenue of diabetes research. Dr. Leissring was recently awarded a five-year career development grant from the American Diabetes Association, which will help support this line of research.

The study was funded by a grant from the National Institutes of Health and a donation from The Unforgettable Fund.

Co-authors include Samer O. Abdul-Hay, Ph.D., Dongcheul Kang, and Melinda McBride, all from Mayo Clinic Florida; and Lilin Li and Ji Zhao, Ph.D., both from The Scripps Research Institute, Florida.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal Reference:

  1. Samer O. Abdul-Hay, Dongcheul Kang, Melinda McBride, Lilin Li, Ji Zhao, Malcolm A. Leissring. Deletion of Insulin-Degrading Enzyme Elicits Antipodal, Age-Dependent Effects on Glucose and Insulin Tolerance. PLoS ONE, 2011; DOI: 10.1371/journal.pone.0020818

Cite This Page:

Mayo Clinic. "Alternative approach to treating diabetes tested." ScienceDaily. ScienceDaily, 10 June 2011. <www.sciencedaily.com/releases/2011/06/110609173716.htm>.
Mayo Clinic. (2011, June 10). Alternative approach to treating diabetes tested. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2011/06/110609173716.htm
Mayo Clinic. "Alternative approach to treating diabetes tested." ScienceDaily. www.sciencedaily.com/releases/2011/06/110609173716.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins